BFC Planning’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$802 Hold
44
– – ﹤0.01% 3206
2026
Q2
$791 Sell
44
-9
-17% -$170 ﹤0.01% 3194
2026
Q1
$1.15K Buy
53
+20
+61% +$387 ﹤0.01% 2719
2025
Q4
$710 Hold
33
– – ﹤0.01% 2864
2025
Q3
$636 Sell
33
-43
-57% -$767 ﹤0.01% 2713
2025
Q2
$1.3K Buy
76
+20
+36% +$853 ﹤0.01% 2395
2025
Q1
$3.58K Buy
56
+12
+27% +$1.26K ﹤0.01% 2140
2024
Q4
$5.35K Hold
44
– – ﹤0.01% 2000
2024
Q3
$5.5K Buy
+44
New +$6.08K ﹤0.01% 1979

Other funds holding SRPT

BFC Planning's SRPT Position: Q3 2026 in Review

BFC Planning held its Sarepta Therapeutics (SRPT) position steady in Q3 2026 at 44 shares worth $802. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

BFC Planning first reported a position in SRPT in Q3 2024 and has held it in 9 quarters since. The position peaked at $5.5K in Q3 2024. 228 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • BFC Planning held 44 shares of Sarepta Therapeutics worth $802 as of Q3 2026.
  • BFC Planning left its Sarepta Therapeutics share count unchanged in Q3 2026.
  • Sarepta Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3206 holding.
  • BFC Planning first reported a position in Sarepta Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Sarepta Therapeutics position peaked at $5.5K in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.